Nomura/Instinet Defends Retrophin (RTRX), Says Selloff is Overdone

Nomura/Instinet analyst Christopher Marai reiterated a Buy rating and $57.00 price target on Retrophin (NASDAQ: RTRX).

The analyst comments "We see the current selloff in the pre-market as overdone—RTRX has $10/sh in cash and a base business that we estimate will generate $180mn in FY19. Further, the company continues to focus on Sparsentan’s ongoing Ph3 studies set to read out in early 2021; we view the Sparsentan program in FSGS as the fundamental value driver going forward, and we believe this conservatively represents $14/sh of our target price (based on just $600mn in sales in 2026E)."

For an analyst ratings summary and ratings history on Retrophin click here. For more ratings news on Retrophin click here.

Shares of Retrophin closed at $17.40 yesterday.

You May Also Be Interested In

• Wedbush Starts Aktis Oncology (AKTS) at Outperform
• Mizuho Reiterates Outperform Rating on Meta Platforms (META) amid ongoing trial
• BMO Capital Starts Prime Medicine (PRME) at Outperform